Dr. Keith C. Bible on Treatments Beyond First-Line Lenvatinib in Thyroid Cancer

March 11, 2016
Keith C. Bible, MD, PhD

Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the impact of lenvatinib in differentiated thyroid cancer. Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options. He adds that while lenvatinib is considered the standard of care in thyroid cancer, these treatments will only function in any given patient for a limited amount of time.